This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
9 Jun 2014

Cherwell Opens Expanded Redipor Prepared Media Manufacturing Facility

Cherwell Laboratories, manufacturer of Redipor prepared microbiological media, has completed an expansion programme at its Bicester-based facility. Initiated in response to a significant increase in demand, Cherwell has doubled the size of its cleanroom manufacturing suite and recruited additional staff to support the higher production capacity. Cherwell is renowned for offering a flexible supply of quality prepared media products, and the expanded facility ensures increasing demand in the UK and mainland Europe can be accommodated.


Cherwell’s continuing growth is partly fuelled by the development of export sales — up 55% in the past 2 years — and the appointment of further European distributors for the Redipor range. Already supported in Italy, Ireland, Poland and Slovenia, Cherwell has recently signed distributor agreements with AcefeSA in Spain and Dorte Egelund in Denmark.  The company has carefully selected partners with the capability to deliver the same quality of service enjoyed by its UK customers.


The company has increased its UK market share through a dedication to customer service and the ability to deliver bespoke prepared media solutions. Many customers are switching to the convenience of Redipor pre-prepared media rather than making their own onsite. Increased pressure by regulators for more environmental monitoring has also led to overall growth in the prepared media market. Notably, demand for Redipor Barrier pack products, for use in isolators where vaporised hydrogen peroxide (VHP) is present, has grown, reflecting the increased use of VHP technology for sterilisation procedures.


Andy Whittard, Managing Director, Cherwell Laboratories commented: “This investment in facilities and capabilities is a clear indication of our commitment to developing our position as a leading supplier of prepared media. Recent market research shows our customers value not just the quality of our products, but increasingly our service and support. Most importantly, we are consistently delivering what our customers want.”


He added: “By developing our export markets through carefully selected partners, we aim to continue growing our UK-based production in a controlled manner, keeping excellent service and the customer at the core of what we do.”

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.